Bexidermil 100 Mg/Ml Solution For Cutaneous Spray 200 Ml

Bexidermil (100 Mg/Ml Solution For Cutaneous Spray 200 Ml)

triethanolamine salicylate

ACTION AND MECHANISM

Trolamine salicylate is a non-steroidal [ANTI-INFLAMMATORY] and [ANALGESIC], from the group of salicylates, which acts by preventing the synthesis of prostaglandins and other prostanoids, by inhibiting cyclooxygenase.

INDICATIONS

- Local symptomatic relief of painful or inflammatory conditions, of traumatic or degenerative origin of the joints, tendons, ligaments and muscles ([ARTHRITIS], periarthritis, [CAPSULITIS], artrosynovitis, [TENOSYNOVITIS], sprains, [MUSCLE CONTRACTURE], [TENDINITIS], [BURSITIS], [CONTUSION], [SPRAIN], [LUMBAL GIA], [TORTICOLLIS], [LUXATION]).

POSOLOGY

DOSAGE:
- Exclusively external cutaneous use.
- Adults and children over 12 years: apply 2 or 3 times a day.
- Do not apply more than 7 days in a row without consulting a doctor.

RULES FOR CORRECT ADMINISTRATION

- Aerosol: The spray should be carried out at a distance of 10 cm from the skin.
- Wash hands after each application.

CONTRAINDICATIONS

[ALLERGY TO SALICYLATES] or [ALLERGY TO NSAIDs].
- Although local administration minimizes the risks derived from its systemic use, topical application, in large areas of the skin, in open wounds, mucous membranes or eczematous skin, for a long time and with the use of occlusive dressings, can cause systemic effects, so it should be remembered that its use is not recommended in patients who have presented allergic reactions (rhinitis, asthma, pruritus, angioedema, urticaria, shock or others), caused by acid acetylsalicylic or other NSAIDs due to the possibility of cross hypersensitivity.

ADVICE TO THE PATIENT

- Avoid contact with eyes and mucous membranes.
- Do not use with occlusive dressings or apply simultaneously in the same area as other topical preparations.
- Do not use for prolonged periods of time or in large areas.
- Use only on intact skin, not on open wounds, mucous membranes or eczematous skin.
- Do not expose the treated area to the sun.
- Wash hands after each application.

SPECIAL WARNINGS

- If symptoms persist for more than 7 days or irritation or worsening occurs, the patient's clinical situation should be evaluated.

INTERACTIONS

They have not been described in cutaneous use, since very low systemic concentrations of the drug are reached, but it will be assessed whether it should be used in conjunction with other topical analgesics.

PREGNANCY

Safety in animals: no data available.

Safety in humans: There are no adequate and well-controlled studies in humans. It can be systematically absorbed through the skin and cross the placenta, although it does so in low amounts. The administration of trolamine salicylate is only accepted if there are no safer therapeutic alternatives, and the benefits outweigh the possible risks.

Effects on Fertility: No specific studies have been conducted in humans.

LACTATION

Safety in animals: no data available.

Safety in humans: It is not known whether trolamine salicylate is excreted in milk. A risk to nursing infants cannot be excluded. A decision should be made whether to discontinue breast-feeding or to interrupt/suspend treatment after considering the benefit of breast-feeding for the child and the benefit of treatment for the mother.

CHILDREN

Its use is not recommended in children under 12 years of age.

ADVERSE REACTIONS

- [ERITEMA], [PRURITUS], feeling of [SKIN IRRITATION] at the application site and local allergic sensitization, effects that subside when the application is stopped.

OVERDOSE

- Symptoms: Its prolonged application and/or in large areas can cause poisoning by salicylates (dizziness, vomiting, ringing in the ears, blurred vision, drowsiness), in which case the medication should be discontinued and go to a medical center.
- Treatment: In case of accidental ingestion, provocation of vomiting and/or gastric lavage or symptomatic treatment, according to medical criteria.

Leaflet Bexidermil 100 Mg/Ml Solution For Cutaneous Spray 200 Ml